Upon immunoblot analysis, we observed that loss of LAT3 expression was associated with increased oxaliplatin resistance (Fig. 5B), leading us to hypothesize that LAT3 may play a role in oxaliplatin resistance in ovarian cancer as well. Here, SLC43A1 is linked to ovarian carcinoma.